Researcher.Life Logo

Expert Opinion on Biological Therapy : Impact Factor & More

eISSN: 1744-7682pISSN: 1471-2598

Aims and Scope of Expert Opinion on Biological Therapy

Expert Opinion on Biological Therapy is a monthly peer-reviewed medical journal covering research on all aspects of biological therapy, including gene therapy and gene transfer technologies, therapeutic peptides and proteins, vaccines and antibodies, and cell- and tissue-based therapies. The journal is published by Taylor & Francis and the editor-in-chief is Michael Morse (Duke University Hospital). The journal was established in 2001 and according to the Journal Citation Reports, it has a 2017 impact factor of 3.974. The journal is also indexed in MEDLINE. Less

Key Metrics

CiteScore
7.2
Eigenfactor
0.005 - 0.01
H-Index
96
Impact Factor
< 5
SJR
Q1Pharmacology
SNIP
1.01
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Expert Opinion on Biological Therapy

Expert Opinion on Biological Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2001
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Expert Opinion on Biological Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Expert Opinion on Biological Therapy

Arian protocol: a phase iii study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer.
  • 20 May 2026
  • Expert opinion on biological therapy
Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial
  • 20 May 2026
  • Expert Opinion on Biological Therapy
Relapse in giant cell arteritis: challenges after discontinuation of targeted therapies.
  • 19 May 2026
  • Expert opinion on biological therapy
Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study
  • 13 May 2026
  • Expert Opinion on Biological Therapy
Immunomodulator therapies in pandemics: lessons from COVID-19 and a blueprint for future outbreaks
  • 7 May 2026
  • Expert Opinion on Biological Therapy
An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer
  • 6 May 2026
  • Expert Opinion on Biological Therapy
Arian protocol: a phase iii study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer.
  • 20 May 2026
  • Expert opinion on biological therapy
Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial
  • 20 May 2026
  • Expert Opinion on Biological Therapy
Relapse in giant cell arteritis: challenges after discontinuation of targeted therapies.
  • 19 May 2026
  • Expert opinion on biological therapy
Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study
  • 13 May 2026
  • Expert Opinion on Biological Therapy
Immunomodulator therapies in pandemics: lessons from COVID-19 and a blueprint for future outbreaks
  • 7 May 2026
  • Expert Opinion on Biological Therapy
An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer
  • 6 May 2026
  • Expert Opinion on Biological Therapy

FAQs on Expert Opinion on Biological Therapy